A collaborative research project in the US has resulted in the creation of...
- 3D printed, ingestible device can provide diagnosis and drug delivery
- Sandoz and Pear Therapeutics get FDA clearance for reSET-O app
- Cardiac electrophysiology set for explosive growth
- FDA clears Contego’s Vanguard balloon angioplasty system
- Can devices fill a gap in the blooming medical cannabis market?
3D printed, ingestible device can provide diagnosis and drug delivery
A collaborative research project in the US has resulted in the creation of an ingestible capsule that is controlled wirelessly with a smartphone app and can detect infections, allergic reactions and other types of conditions inside the body.
New app for opioid use disorder shows the potential of digital therapies
In April 2018, Pear Therapeutics and Sandoz formed a commercialisation partnership for Pear’s leading pipeline assets, reSET and re-SET-O. The deal would combine Pear’s expertise in software-based therapeutics with Sandoz’s global reach and strong marketing force.
Sandoz and Pear Therapeutics get FDA clearance for reSET-O app
Novartis subsidiary Sandoz and Pear Therapeutics have obtained US Food and Drug Administration (FDA) 510(k) clearance for the use of the reSET-O mobile application, which treats opioid use disorder (OUD).
Cardiac electrophysiology set for explosive growth
While currently relatively small at $4.6B this year, electrophysiology is expected to consistently grow at an extremely high rate of 4.60% in the foreseeable future, leading to a market size of $5.8B in five years.
FDA clears Contego’s Vanguard balloon angioplasty system
Medical devices firm Contego Medical has received the US Food and Drug Administration (FDA) 510(k) clearance for the Vanguard IEP Peripheral Balloon Angioplasty System, which treats peripheral vascular disease.
Can devices fill a gap in the blooming medical cannabis market?
With the legalisation of cannabis in Canada, interest has grown internationally, extending far beyond the North American borders into both Europe and Asia-Pacific.
NICE approves heart valve repair procedure for NHS patients
The National Institute for Health and Care Excellence (NICE) has approved a minimally invasive heart valve repairing procedure for NHS patients who would not be able to have conventional open-heart surgery.
Antibiotic-resistance threat grows as more patients go under the knife
Minimally invasive surgeries have spurred a growth in procedures, especially for patients with conditions that are difficult to treat, such as osteoarthritis.
New nanomaterial could revolutionise cartilage regeneration
Osteoarthritis is highly prevalent amongst the global population, with over 20 million patients estimated to be affected in the US alone.
NeuroPace reports positive long-term results of Next-Gen RNS system
NeuroPace has reported positive results from a long-term study of its Next-Gen RNS System to treat refractory epilepsy in the US.
Read our magazine
Medical Technology is the essential reading material for decision-makers in the medical device industry, bringing you the latest news and analysis in an exciting, interactive format.